Abstract:Key PointsHigh-mobility group box 1 protein (HMGB1) is a highly conserved nuclear protein that has a surprising extracellular role. Not only does it bind DNA, increasing access to transcription factors, but it also recruits cells across endothelial barriers and promotes the local production of tumour-necrosis factor (TNF), interleukin-6 (IL-6) and interferon-γ.HMGB1 is released from necrotic cells and is secreted by activated macrophages, natural killer cells and mature dendritic cells, but it is not produced by neutrophils. HMGB1 is a 'leaderless' cytokine, requiring specialized means to gain access to the immunological synapse or to be secreted.By contrast, after DNA damage as a result of apoptotic cell death, ultraviolet-light irradiation or platination, HMGB1 is sequestered in the nucleus.During sepsis, HMGB1 release occurs considerably later than macrophage secretion of the classical early pro-inflammatory mediators TNF and IL-1.Receptors for HMGB1 include RAGE (receptor for advanced glycation end-products), Toll-like receptor 2 (TLR2) and TLR4, and possibly other as-yet-unknown receptors.RAGE is encoded in the MHC class III region and is expressed as both a transmembrane molecule — which directly interacts with extracellular-signal-regulated kinase 1 (ERK1) and/or ERK2 and drives activation of the mitogen-activated protein kinase p38 and nuclear factor-κB — and as a soluble molecule. Soluble RAGE blocks RAGE ligands, including HMGB1 and S100 proteins.The expression of RAGE by activated endothelia promotes leukocyte recruitment, through the interaction of RAGE with myeloid cells that express the β2-integrin MAC1, and this is augmented in the presence of S100 proteins. Macrophages also express HMGB1 at the cell surface when they are activated, facilitating their recruitment through interaction with RAGE expressed by endothelial cells and enabling their translocation across endothelial barriers.Controlling HMGB1 activity and release is an approach that is being developed as an experimental therapy for patients with sepsis, arthritis, cancer and other disorders.

Regulation of Posttranslational Modifications of HMGB1 During Immune Responses.

Post-Translational Modification of HMGB1 Disulfide Bonds in Stimulating and Inhibiting Inflammation

Immunological Significance of HMGB1 Post-Translational Modification and Redox Biology

HMGB1 in health and disease

The multifunctional protein HMGB1: 50 years of discovery

Redox modifications of cysteine residues regulate the cytokine activity of HMGB1

The mechanism of HMGB1 secretion and release

HMGB1 as a therapeutic target in disease

Targeting Inflammation Driven by HMGB1

High Mobility Group Box 1: Biological Functions and Relevance in Oxidative Stress Related Chronic Diseases

Regulation of HMGB1 release by inflammasomes

The Redox Protein High-Mobility Group Box 1 in Cell Death and Cancer

The redox protein HMGB1 in cell death and cancer

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

HMGB1 as a DNA-binding cytokine

The Effect and Regulatory Mechanism of High Mobility Group Box-1 Protein on Immune Cells in Inflammatory Diseases

The Janus face of HMGB1 in heart disease: a necessary update

HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection

HMGB1: Endogenous Danger Signaling

HMGB1: An overview of its roles in the pathogenesis of liver disease

Activation of Toll-Like Receptor 5 Immune Signaling by Hmgb1